Purple Biotech Ltd. Form 6-K Summary
Business Context and Reporting Period
Purple Biotech Ltd., a foreign private issuer headquartered in Rehovot, Israel, filed this Form 6-K on March 17, 2026. The report covers the month of March 2026 and primarily serves to disclose a corporate announcement regarding regulatory compliance.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The material change disclosed is the company's regaining of compliance with the Nasdaq Minimum Bid Price Requirement. This status was confirmed via a press release issued on March 17, 2026, which is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the implication of the prior non-compliance with Nasdaq listing standards. The document focuses solely on the resolution of the minimum bid price issue.
Investor Verification Checklist
- Verify the current trading price of Purple Biotech shares to confirm sustained compliance with Nasdaq Minimum Bid Price requirements.
- Review the attached Exhibit 99.1 press release for details on the specific actions taken to regain compliance.
- Check subsequent filings for any updated financial data, as this Form 6-K contains no financial metrics.